Država: Irska
Jezik: angleščina
Source: HPRA (Health Products Regulatory Authority)
Enrofloxacin
Elanco GmbH
QJ01MA90
Enrofloxacin
100 milligram(s)/millilitre
Solution for injection
POM: Prescription Only Medicine as defined in relevant national legislation
enrofloxacin
Authorised
1988-10-01
Health Products Regulatory Authority SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Baytril 100 mg/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml solution contains: Active Substance Enrofloxacin 100 mg Excipients n-butyl alcohol 30 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear light-yellow solution. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle, sheep, goats and pigs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES _Cattle _ Treatment of infections of the respiratory tract caused by enrofloxacin susceptible strains of _Pasteurella multocida_, _Mannheimia _ _haemolytica _and _Mycoplasma _spp. Treatment of acute severe mastitis caused by enrofloxacin susceptible strains of _Escherichia coli_. Treatment of infections of the alimentary tract caused by enrofloxacin susceptible strains of _Escherichia coli. _ Treatment of septicaemia caused by enrofloxacin susceptible strains of _Escherichia coli_. Treatment of acute mycoplasma-associated arthritis due to enrofloxacin susceptible strains of _Mycoplasma bovis _in cattle less than 2 years old. _Sheep _ Treatment of infections of the alimentary tract caused by enrofloxacin susceptible strains of _Escherichia coli. _ Treatment of septicaemia caused by enrofloxacin susceptible strains of _Escherichia coli. _ Treatment of mastitis caused by enrofloxacin susceptible strains of _Staphylococcus aureus _and _Escherichia coli. _ _ _ _Goats _ Treatment of infections of the respiratory tract caused by enrofloxacin susceptible strains of _Pasteurella multocida _and _Mannheimia haemolytica. _ Treatment of infections of the alimentary tract caused by enrofloxacin susceptible strains of _Escherichia coli. _ Treatment of septicaemia caused by enrofloxacin susceptible strains of _Escherichia coli. _ Treatment of mastitis caused by enrofloxacin susceptible strains of _Staphylococcus aureus _and _Escherichia coli. _ _ _ _Pigs _ Treatment of infections of the resp Preberite celoten dokument